Rx Response, the biopharmaceutical supply chain initiative to ensure patient access to medications during natural disasters and other emergencies, has established a new membership structure to allow  individual companies to become direct members.


Rx Response, biopharmaceutical supply chain, natural disasters, emergencies, access to medications, Erin Mullen, 501(c)(3) nonprofit organization, disaster preparedness, diasaster response


































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Retail News Breaks Archives

Rx Response expands access to disaster response services

March 20th, 2014

WASHINGTON – Rx Response, the biopharmaceutical supply chain initiative to ensure patient access to medications during natural disasters and other emergencies, has established a new membership structure to allow  individual companies to become direct members.

In addition, Rx Response announced Wednesday that the IRS has approved its application to become a 501(c)(3) nonprofit organization, which will make it easier for foundations, other nonprofit groups and government agencies to provide grants.

Rx Response noted that the new membership structure enables drug supply chain companies to enhance their disaster preparedness and diasaster response capabilities by tapping Rx Response's accurate and timely information, direct support during disasters, government relationships and industry networking.

Individual supply chain companies that join Rx Response will also increase the program's situational awareness by providing a broader source of reports about the impact of a disaster on the supply chain members.

"We're very excited to begin recruiting individual supply chain members to join Rx Response," Erin Mullen, executive director of Rx Response, said in a statement. "Many of the companies we'll be talking with have already invested in disaster planning, but their active involvement in Rx Response will significantly boost their readiness. It will also open new doors for them to work with federal and state officials who can help companies address challenges posed by large-scale disasters.

"At the same time, adding supply chain companies to our roster will significantly boost the situational awareness we can rely on in the supply chain and offer to our government partners," Mullen noted. "This will allow federal and state officials to make more informed decisions about where to direct resources in a disaster to help address any threats to the bio-pharmaceutical supply chain."

Launched in 2007, Rx Response was developed in response to Hurricane Katrina and the threat of pandemic influenza. The initiative provides a platform through which the entire biopharmaceutical supply system can easily communicate to coordinate pre-disaster planning and post-disaster response. Rx Response also serves as a single point of contact through which government officials and supply chain members can collaborate to share information and address challenges impacting the supply system.

Rx Response's actions following Hurricane Sandy in 2012 drew praise from then-Homeland Security Secretary Janet Napolitano.

Along with Mullen, initial members of the newly formed Rx Response board of directors include Phyllis Arthur of the Biotechnology Industry Organization (BIO), Perry Fri of the Healthcare Distribution Management Association (HDMA), Kathleen Jaeger of the National Association of Chain Drug Stores (NACDS) and the NACDS Foundation, Mary Lockyear of the American Red Cross, Del Persinger of the Pharmaceutical Research and Manufacturers of America (PhRMA) and Christine Simmon of the Generic Pharmaceutical Association of America (GPhA).

Advertisement